Spinal cord injury causes liver pathology and metabolic dysfunction
脊髓损伤导致肝脏病理和代谢功能障碍
基本信息
- 批准号:10589087
- 负责人:
- 金额:$ 53.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-01 至 2026-03-31
- 项目状态:未结题
- 来源:
- 关键词:AcuteAdrenergic AgentsAutonomic nervous systemBiological ModelsCardiovascular DiseasesCause of DeathCellsCentral obesityCeramidesChronicComplexDataDevelopmentDiseaseDisinhibitionDyslipidemiasEatingEndocrineEnzymesFatty acid glycerol estersGeneral PopulationGeneticGenetic TranscriptionGoalsHealthHepaticHepatocyteHigh Fat DietHomeostasisHyperactivityHyperglycemiaHypertensionIndividualInflammationInflammation MediatorsInflammatoryInjuryInsulin ResistanceInterruptionInterventionKupffer CellsLinkLipidsLiverLiver diseasesLiver neoplasmsLiver parenchymaLongevityMediatorMetabolicMetabolic dysfunctionMetabolic syndromeMolecular TargetMorbidity - disease rateNF-Kappa B p65NF-kappa BNeuronsNon obeseNon-Insulin-Dependent Diabetes MellitusNorepinephrineNutritional and Metabolic DiseasesObesityOperative Surgical ProceduresOrganPathologyPathway interactionsPlayPopulationPrevalenceRattusRecoveryReportingRiskRodentRoleSignal InductionSignal TransductionSpinal CordSpinal cord injuryStrokeSympathectomySympathetic Nervous SystemSystemSystemic diseaseTNF geneTechnologyTestingTransgenic MiceTransgenic OrganismsWorkcardiometabolic riskcell injurydesigndesigner receptors exclusively activated by designer drugsdiabetes riskexperimental studyhigh riskimprovedinsightlipid metabolismlipidomicsliver functionliver inflammationmouse geneticsnegative affectneurological recoverynon-alcoholic fatty liver diseasenonalcoholic steatohepatitisnovelpre-clinicalsedentary lifestyleserine palmitoyltransferasesingle-cell RNA sequencingstatisticstherapeutic target
项目摘要
Spinal cord injured (SCI) individuals have significantly reduced lifespans compared to the general population, a
statistic that has not changed in 30 years. One reason is “endocrine, metabolic and nutritional diseases”, which
are increasing at alarming rates in the SCI population (2019 Models Systems report). This is evidenced by SCI
individuals having increased prevalence of Metabolic Syndrome (MetS), the complications of which put them at
a higher risk for diabetes, cardiovascular disease and stroke compared to the general population. A central
feature of MetS and contributor to morbidity is hepatic pathology in the form of non-alcoholic steatohepatitis
(NASH), a severe form of nonalcoholic fatty liver disease (NAFLD). NASH includes hepatic lipid accumulation
(steatosis) and inflammation, which in turn cause hepatocyte damage and release of pro-inflammatory
mediators. NASH likely facilitates subsequent systems-wide pathology after SCI. Experiments in this proposal
are designed to identify mechanisms that initiate and sustain NASH in acute and chronic SCI. Focus will be on
increased sympathetic input to the liver and consequent intracellular changes in the liver that drive
inflammation and fat accumulation. We hypothesize that excess sympathetic input to the liver after SCI
initiates pro-inflammatory cascades involving TNFa and NFkB, which in turn initiate hepatic fat
accumulation and prolonged inflammation. We will use transgenic mouse technology as well as unbiased -
omics approaches to comprehensively identify cellular changes in the liver induced by SCI that drive
“neurogenic” NASH and subsequent features of MetS. Our long-term goal is to identify therapeutic targets that
can interrupt the dysfunctional spinal cord/liver axis after SCI to restore liver homeostasis and improve overall
metabolic health.
与普通人群相比,脊髓损伤(SCI)患者的寿命显著缩短。
30年来从未改变过的统计数据。其中一个原因是“内分泌、代谢和营养疾病”。
SCI人群正以惊人的速度增长(2019 Models Systems报告)。SCI证明了这一点。
代谢综合征(METS)患病率增加的个人,其并发症使他们处于
与普通人群相比,患糖尿病、心血管疾病和中风的风险更高。一个中环
非酒精性脂肪性肝炎的肝脏病理表现是蛋氨酸的特点和致病因素
(NASH),一种严重的非酒精性脂肪性肝病(NAFLD)。NASH包括肝脏脂肪堆积
(脂肪变性)和炎症,进而导致肝细胞损伤和促炎因子的释放
调解人。NASH可能促进了脊髓损伤后随后的全系统病理。此提案中的实验
旨在确定在急性和慢性脊髓损伤中启动和维持NASH的机制。重点将放在
增加对肝脏的交感神经输入,以及随之而来的肝脏细胞内变化
炎症和脂肪堆积。我们推测脊髓损伤后过多的交感神经输入到肝脏
启动包括TNFa和NFkB在内的促炎级联反应,进而启动肝脏脂肪
积聚和长时间的炎症。我们将使用转基因小鼠技术以及无偏见的-
组学方法全面识别脊髓损伤引起的肝脏细胞变化
“神经性”NASH和METS的后续特征。我们的长期目标是确定治疗靶点
可以阻断脊髓损伤后功能障碍的脊髓/肝轴,恢复肝脏内环境平衡,全面改善
新陈代谢健康。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DANA M MCTIGUE其他文献
DANA M MCTIGUE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DANA M MCTIGUE', 18)}}的其他基金
Spinal cord injury causes liver pathology and metabolic dysfunction
脊髓损伤导致肝脏病理和代谢功能障碍
- 批准号:
10210615 - 财政年份:2021
- 资助金额:
$ 53.75万 - 项目类别:
Spinal cord injury causes liver pathology and metabolic dysfunction
脊髓损伤导致肝脏病理和代谢功能障碍
- 批准号:
10377530 - 财政年份:2021
- 资助金额:
$ 53.75万 - 项目类别:
Regulation of myelination after spinal cord injury
脊髓损伤后髓鞘形成的调节
- 批准号:
10187660 - 财政年份:2018
- 资助金额:
$ 53.75万 - 项目类别:
Regulation of myelination after spinal cord injury
脊髓损伤后髓鞘形成的调节
- 批准号:
10412019 - 财政年份:2018
- 资助金额:
$ 53.75万 - 项目类别:
Ohio State University Neuroscience Center Core-Core B
俄亥俄州立大学神经科学中心核心-核心 B
- 批准号:
10005507 - 财政年份:2017
- 资助金额:
$ 53.75万 - 项目类别:
Restoring Iron Homeostasis to Promote Recovery after Spinal Cord Injury
恢复铁稳态以促进脊髓损伤后的恢复
- 批准号:
8703831 - 财政年份:2013
- 资助金额:
$ 53.75万 - 项目类别:
Restoring Iron Homeostasis to Promote Recovery after Spinal Cord Injury
恢复铁稳态以促进脊髓损伤后的恢复
- 批准号:
8599191 - 财政年份:2013
- 资助金额:
$ 53.75万 - 项目类别:
Restoring Iron Homeostasis to Promote Recovery after Spinal Cord Injury
恢复铁稳态以促进脊髓损伤后的恢复
- 批准号:
8893177 - 财政年份:2013
- 资助金额:
$ 53.75万 - 项目类别:
Oligodendrocyte Genesis after Spinal Cord Injury
脊髓损伤后少突胶质细胞的发生
- 批准号:
7994743 - 财政年份:2009
- 资助金额:
$ 53.75万 - 项目类别:
Oligodendrocyte Genesis after Spinal Cord Injury
脊髓损伤后少突胶质细胞的发生
- 批准号:
8386663 - 财政年份:2009
- 资助金额:
$ 53.75万 - 项目类别:
相似海外基金
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
- 批准号:
8358448 - 财政年份:2012
- 资助金额:
$ 53.75万 - 项目类别:
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
- 批准号:
8517552 - 财政年份:2012
- 资助金额:
$ 53.75万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7952159 - 财政年份:2009
- 资助金额:
$ 53.75万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7952152 - 财政年份:2009
- 资助金额:
$ 53.75万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7719194 - 财政年份:2008
- 资助金额:
$ 53.75万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7605416 - 财政年份:2007
- 资助金额:
$ 53.75万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7605425 - 财政年份:2007
- 资助金额:
$ 53.75万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7378753 - 财政年份:2006
- 资助金额:
$ 53.75万 - 项目类别:
Adrenergic Agents for Methamphetamine: Outpatient Trials
甲基苯丙胺肾上腺素药物:门诊试验
- 批准号:
6825160 - 财政年份:2004
- 资助金额:
$ 53.75万 - 项目类别:
ADRENERGIC AGENTS FOR CARDIOPULMONARY RESUSCITATION
用于心肺复苏的肾上腺素能药物
- 批准号:
2702283 - 财政年份:1997
- 资助金额:
$ 53.75万 - 项目类别: